PET Related Published Articles
1. Rozenman, Y., Mereuta, A., Schechter, D., Mosseri, M., Lotan, C., Nassar, H., Weiss, T., Hasin, Y., Chisin, R., Gotsman, M.S. Long term outcome of patients with very long stents for treatment of diffuse coronary disease. American Heart Journal, 138:441-445, 1999.
2. Chisin, R. Nuclear Medicine in Head and Neck Oncology: Reality and Perspectives. J. Nucl. Med., 40:91-95, 1999.
3. Klein, M., Freedman, N., Mishani, E., Gimon, Z., Lotem, M., Chisin, R. PET and lymphoscintigraphic evaluation of malignant melanomas. Nuklear Medizin, 39:56-61, 2000.
4. Freedman, N., Schechter, D., Klein, M., Marciano, R., Rozenman, Y., Chisin, R. Retrospective Comparison between Rb-82 PET and TI-201 SPECT Myocardial Perfusion Imaging: Insights into SPECT Attenuation Artifacts in Normal and Overweight Subjects. Clinical Nuclear Medicine, 25:1019-1023, 2000.
5. Nunez, R., Yeung, H., and Chisin, R*. Fluorine-18 FDG Positron Emission Tomography in Advanced Nasopharyngeal Carcinoma. Clinical Nuclear Medicine, 25:731-733, 2000.
6. Akhurst, T., and Chisin, R*. Hybrid PET/CT machines: optimized PET machines for the new milIennium? Letter to the Editor. Journal of Nuclear Medicine, 41:961-962, 2000.
7. Chisin, R. and Macapinlac, H.A. The Indications of FDG-PET in Neck Oncology. Radiological Clinics of North America, 38:999-1011, 2000.
8. Bocher, M., Mishani, E. The contribution of Positron Emission Tomography-PET to patient management in oncology. J. of the Israel Medical Association, 139:64, 2000.
9. Rubinstein, R., Broier, R., Chisin, R. The Contribution of FDG-PET to Diagnosis and Management of Lung Cancer - First Results. Harefuah (in Hebrew), 140:100-103, 2001.
10. Ramos, C.D., Erdi, Y.E., Gonen, M., Riedel, E., Yeung, H.W.D., Macapinlac, H.A., Chisin, R.*, Larson, S.M. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back projection. European Journal of Nuclear Medicine, 28:155-164, 2001.
11. Ramos, C.D., Chisin, R.*, Yeung, H.W.D., Larson, S.M., Macapinlac, H.A. Incidental focal thyroid uptake on FDG-PET scans should not be overlooked. Clinical Nuclear Medicine, 26: 193-197, 2001.
12. Bocher, M., Chisin, R., Parag, Y., Freedman, N., Meir-Weil, Y., Lester, H., Mishani, E., and Bonne, O. Pornographic Clip:. A 150-H2O PET Study in Heterosexual Men. Neuroimage, 14:105-117, 2001.
13. Sosna, J., Chisin, R., Klein, M. FDG-PET imaging of the effect of an intra-uterine device. Clin. Nucl. Med., 27:128-129, 2002.
14. Chisin, R., Klein, M. La tomographie par émission de positrons (TEP), une technique d'imagerie médicale révolutionnaire. Journal du MEDIF, 2002, No 13.
15. Lossos, A., Reches, A., Gal, A., Newmann, J.P., Soffer, D., Gomori, J.M., Bocher, M., Ekstein, D., Biran, I., Meiner, Z., Abramsky, M., Rosenmann, H. Frontotemporal dementia and parkinsonism with the p301 s tau gene mutation in a Jewish family. Journal of Neurology, 250(6):733-740, 2003.
16. Freedman, N.M.T.*, Sundaram, S.K., Kurdziel, K., Carrasquillo, J.A., Whatley, M., Carson, J.M., Sellers, D., Libutti, S.K., Yang, J.C., Bacharach, S.L. Comparison of SUV and Patlak slope to monitor cancer therapy using serial PET scans. Eur. J. Nucl. Med., 30:46-53, 2003.
17. Gilboa, A., Shalev, A.Y., Laor, L., Lester, H., Louzoun, Y., Chisin, R., Bonne, O. Functional connectivity of the prefrontal cortex and the amygdala in posttraumatic stress disorder. Biol. Psychiatry, 55(3):263-272, 2004.
18. Biran, T., Malhi, S., Marciano, R., Weininger, J., Chisin, R. Measurements of Occupational Exposure for Technologists Performing F-18 FDG PET Scans. Health Physics. In press, 2004.
Cyclotron Related Published Articles
1. Ben-David, I., Mishani, E., Rozen, S. Tert-Butyl Hypofluorite - An Electrophilic tert-Butoxylation Agent. J. Org. Chem., 63:4632, 1998.
2. Mishani, E., Lifshits, N., Osavistky, A., Kaufman, J., Ankry, N., Tal, N., Chisin, R. Radiation Levels in Cyclotron-Radiochemistry Facility measured by A Novel Comprehensive Computerized Monitoring System. Nucl. Instr. Meth. Phys. Res. A, 425:332-342, 1999.
3. Mishani, E., Bonasera, T.A., Rozen, Y., Ortu, G., Gazit, A., Levitzki, A. Fluorinated EGFR- TK inhibitor-based tracers for PET. J. Labl. Comp. Radiopharm., 42:27, 1999.
4. Ben David, I., Rechavi, D., Mishani, E., Rozen, S. A Novel synthesis of trifluoromethyl ethers via xanthates, utilizing BrF3. J. of Fluorine Chemistry, 97:75, 1999.
5. Bonasera, T.A., Ortu, G., Rozen, Y., Krais, R., Freedman, N., Chisin, R., Gazit, A., Levitzki, A., and Mishani, E. Potential 18F-Labeled Biomarkers for Epidermal Growth Factor Receptor Tyrosine Kinase. J. of Nucl. Med. and Biol., 28 (4):359-374, 2001.
6. Mishani, E., Ben David, I., Rozen, Y., Ortu, G., Levitzki, A. Carbon-II Labeled Irreversible Inhibitors for Mapping Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR- TK). J. Labl. Comp. Radiopharm., 44:94, 2001.
7. Mishani, E., Ben David, I. [C-11] Acryloyl Chloride- A Fully Automated Preparation and Reaction with Model Amine. J. Labl. Comp. Radiopharm., 44:475, 2001.
8. Mishani, E., Ben-David, I., Rozen, Y., Laki, D., Bocher, M., Chisin, R. [C-11]Choline - Automated Preparation and Clinical Utilization. J. Labl. Comp. Radiopharm., 44:379, 2001.
9. Ortu, G., Ben-David, I., Rozen, Y., Levitzki, A., Mishani, E. Biological Evaluation of A Novel C-11 Labelled Irreversible EGFRTK Inhibitor. The Quar. J. of Nucl. Med., 45:7, 2001.
10. Mishani, E., Ben-David, I., Rozen, Y. Improved method for the quality assurance of [C-11]choline. J. of Nucl. Med. and Biol., 29:359, 2002.
11. Ortu, G., Ben-David, I., Rozen, Y., Freedman, N.M., Chisin, R., Levitzki, A., Mishani, E. In-vitro and In-vivo investigation of an irreversible labeled EGFr inhibitor (ML03) and its potential as PET biomarker in Cancer and feasibility as an anticancer drug. Int. J. Cancer, 101:360-370, 2002.
12. Ben-David, I., Rozen, Y., Ortu, G., and Mishani, E. Radiosynthesis of a Novel Positron Emission Tomography Biomarker Targeting Epiderman Growth Factor Receptor Tyrosine Kinase Via [11C]Acryloyl Chloride Labeling Sunthon. Appl. Rad. And Isotp., 58:209-217, 2003.
13. Even-Sapir, E., Metser, U., Flusser, G., Zuriel, L., Kollender, Y., Lerman, H., Lievshitz, G., Ron, I. and Mishani, E. Assessment of malignant skeletal disease: Initial experience with 18F-Fluoride PET/CT and comparison between 18F-Fluoride PET and 18F-Fluoride PET/CT. J. Nuc. Med., 45(2):272-278, 2004.
14. Mishani, E., Abourbeh, G., Rozen, Y., Jacobson, O., Laky, D., Ben David, I., Levitzki, A., Shaul, M. Novel Carbon-11 Labeled 4-Dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: Potential PET Bioprobes for Molecular Imaging of EGFR-positive Tumors. J. of Nucl. Med. and Biol., 31(4):469-476, 2004.
15. Shaul, M., Abourbeh, G., Jacobson, O., Rozen, Y., Laky, D., Levitzki A. and Mishani, E. Novel Iodine-124 Labeled EGFR Inhibitors as Potential PET Agents for Molecular Imaging in Cancer. Bioorg. Med. Chem., 12:3421-3429, 2004.
16. Barda, Y., Cohen, N., Lev, V., Ben-Aroya, N., Koch, Y., Mishani, E., Fridkin, M., Gilon, C. Backbone metal cyclization: novel 99mTc labeled GnRH analog as potential SPECT molecular imaging agent in cancer. J. of Nucl. Med. and Biol., 31(7):921-933, 2004.
PET Related Abstracts
1. Freedman, N.M.T.*, Andrich, M.P., Bacharach, S.L., Chisin, R., Fraker, D.L. SUV: Importance of correct normalization in prediction of clinical outcome. Presented to the SNM Mideastern Chapter Meeting, Rockville, Maryland, USA, May 1995.
2. Chisin, R. Brain PET Imaging: Basics and Indications. In Aging in the Mediterranean and the Middle East. Ed. G. Friedman and Jenny Brodsky, p. 201-208, 1998.
3. Chisin, R., Freedman, N., Marciano, R., Taylor, C., Schechter, D. A Retrospective Evaluation of one year of Cardiac PET imaging at Hadassah Hospital Using Rubidium-82 and the Positron Corporation HZL PET Canner. The19th Conference of the Israeli Nuclear Societies, Herzlya, Israel, December 9-10, 1996.
4. Chisin, R., Freedman, N., Marciano, R., Taylor, C., Schechter, D. A Retrospective Evaluation of Cardiac PET Imaging at Hadassah Hospital Using Rubidium 82. Annual Meeting of the Israeli Cardiology Society, Tel-Aviv, Israel, April 14-15, 1997.
5. Freedman, N., Schechter, D., Klein, M., Marciano, R., Taylor, C., Chisin, R. Cardiac SPECT Attenuation Artifacts - a Phenomenon of Obesity Only? Comparison with Rb-82 PET. Society of Nuclear Medicine 44th Annual Meeting, San Antonio, Texas, USA. June 1-5, 1997.
6. Chisin, R., Klein, M., Freedman, N., Mishani, E., Shiloni, E., Gimon, Z., Lotem, M. PET and Lymphoscintigraphic Evaluation of Malignant Melanomas: The Hadassah Hospital Experience. 10th Annual International PET Conference, Boston, Massachussets, USA, 1998. Lecture.
7. Chisin, R., Klein, M., Krausz, Y., Freedman, N., Sichel, J.- Y. Nuclear Medicine (Planar, SPECT and PET Imaging) in Head and Neck Oncology. Fourth Jerusalem Imaging Meeting, Jerusalem, Israel, January 13-14, 1999.
8. Klein, M., Freedman, N., Mishani, E., Gimon, Z., Lotem, M., Chisin, R. PET and lymphoscintigraphic evaluation of malignant melanomas. Fourth Jerusalem Imaging Meeting, Jerusalem, Israel, January 13-14, 1999.
9. Karger, J. C., Chisin, R. Positron Emission Tomography. Annual Meeting of the Israeli Society for Information Systems in Medicine, Kfar Hamaccabiah, Israel, June 3, 1999.
10. Krausz, Y.*, Strauss, H.W., Goris, M.L., Segall, G.M. Comparison of FDG-PET and Gallium scan in staging and follow-up of patients with Hodgkin's disease. The Society of Nuclear Medicine 46th Annual Meeting, Los Angeles, CA, USA, June 1999. Received an outstanding score; Dr. P. Conti.
11. Chisin, R., Bocher, M., Freedman, N., Lester, H., Shalev, A., Bonne, O. A symptom provocation brain PET study in PTSD patients. MEDAX 2001, Tel-Aviv, Israel, Sept. 5, 2001.
12. Bocher, M., Cohen, M., Freedman, N., Chisin, R. Hadassah hospital experience using FDG-PET for localization of an epileptic focus in patients with intractable epilepsy. MEDAX 2001, Tel-Aviv, Israel, Sept. 5, 2001.
13. Bocher, M., Bonne, 0., Parag, Y., Freedman, N., Meir-Weill, Y., Lester, H., Mishani, E. and Chisin, R. Cerebral activation associated with sexual arousal in response to a pornographic clip: a ISO-H2O PET study in heterosexual men. 48th Annual Meeting of the Society of Nuclear Medicine, Toronto, Canada, June 23-28, 2001.
14. Bocher, M., Weininger, J., Yozefovich, B., Wilk, M., and Chisin, R. Evaluation of Reconstruction Methods of F-18 FDG PET Images on a Gamma Camera with X-Ray Transmission. 49th Annual Meeting of the Society of Nuclear Medicine, Los Angeles, CA, USA, June 15-19, 2002.
15. Chisin, R., Freedman, N., Rubinstein, R., Mishani, E., Bocher, M., Lester, H., Shoshan, Y., Gomori, J.M., and Siegal, T. Can C-ll Choline PET (CHOL-PET) Contribute to the Differentiation of Recurrent High-Grade Brain Tumor from Post-Radiation Necrosis (PRN?). 49th Annual Meeting of the Society of Nuclear Medicine, Los Angeles, CA, USA, June 15-19, 2002.
16. Barkai, G., Bonne, 0., Lester, H., Sapoznikov, D., Freedman, N., Sha1ev, A., and Chisin, R. Brain Activation Related to Peripheral Arousal During Guided Traumatic Imagery in Post Traumatic Imagery in Post Traumatic Stress Disorder (PTSD). 49th Annual Meeting of the Society of Nuclear Medicine, Los Angeles, CA, USA, June 15-19, 2002.
17. Freedman, N., Chisin, R., Rubinstein, R., Shoshan, Y., Siegal, T. Factor Analysis (FA) in the evaluation of dynamic PET brain tumor imaging with II C-choline. 49th Annual Meeting of the Society of Nuclear Medicine, Los Angeles, CA, USA, June 15-19, 2002.
18. Freedman, N.M.*, Sundaram, S.K., Carson, J.M., Libutti, S.K., Whatley, M., Sellers, D., Carrasquillo, J.A., Bacharach, S.L. Patlak Tumor Images Revisited. 49th Annual Meeting of the Society of Nuclear Medicine, Los Angeles, CA, USA, June 15-19, 2002.
19. Sundaram, S.K., Freedman, N.M.*, Carrasquillo, J.A., Carson, J.A., Libutti, S.K., Whately, M., Sellers, D., Bacharach, S.L. Can Simplified Kinetic Patlak Analysis be used to Monitor Tumor Therapy? 49th Annual Meeting of the Society of Nuclear Medicine, Los Angeles, CA, USA, June 15-19, 2002.
20. Weininger, J., Biran, T., Marciano, R., Malchi, S., Chisin, R. Measurements of Radiation Doses to PET Technologists from F-18 FDG. EANM Congress, Vienna, Austria, September 2002.
21. Bar-Haim Erez, A., Katz, N., Bocher, M., Lester, H., Chisin, R., Freedman, N., Cohen, A., Abramsky, O. Neural mechanism of visual attention in unilateral spatial neglect following stroke: a (O-15)-water brain activation PET study. 50th Annual Meeting of the Society of Nuclear Medicine, New Orleans, Louisiana, USA, June 2003.
22. Klein, M., Fox, M., Kopelewitz, B., Weintraub, M., Chisin R. Specific features of FDG-PET scanning in a pediatric population. 51th Annual Meeting of the Society of Nuclear Medicine, Philadelphia, Pennsylavania, USA, June 2004.
23. Klein, M., Fox, M., Kopelewitz, B., Krausz, Y., Weintraub, M., Chisin R. Role of FDG-PET in the follow-up of pediatric lymphoma. 51th Annual Meeting of the Society of Nuclear Medicine, Philadelphia, Pennsylavania, USA, June 2004.
24. Krausz, Y.*, Guralnik, L., Bettman, L., Bar-Shalom, R., Keidar, Z., Israel, O. The incremental value of PET/CT over FDG-PET in the assessment of patients with Differentiated Thyroid Cancer. 51th Annual Meeting of the Society of Nuclear Medicine, Philadelphia, Pennsylavania, USA, June 2004.
* In collaboration with other centers.
Cyclotron Related Abstracts
1. Mishani E., Loewenthal, E., Tal, N., Arad, M., Kaufman, Y., Osovizky, A. Safety Control And Radiation Monitoring System for Cyclotron Sites. The Second Regional Mediterranean Congress on Radiation Protection, Tel-Aviv, Israel, 1997. Lecture.
2. Ghyoot, M., Schmitz, F., Verbruggen, R., Boeyen, P.E., Mishani, E., Bormans, G. Improvement in Fluoride Production in IBA target. Proceedings of the Seventh Workshop on Targetry and Target Chemistry, Heidelberg, Germany, 1997. Lecture.
3. Mishani, E., Osavistky, A., Tal, N., Chisin, R. Radiation Levels in Cyclotron Radiochemistry Facility. 10th Annual International PET Conference, Boston, Massachussets, USA, 1998. Poster.
4. Mishani, E., Bonasera, T.A., Rozen, Y., Ortu, G., Gazit, A., Levitzki, A. Potential PET Biomarkers for Epidermal Growth Factor Receptor Tyrosine Kinase. 2000 International Chemical Congress of Pacific Basin Societies, Honolulu, Hawai, 2000. Poster.
5. Ortu, G., Ben-David, I., Rozen, Y., Levitzki, A., Mishani, E. Biological Evaluation of A Novel C-11 Labelled Irreversible EGFRTK Inhibitor. 12th International Symposium on Radiopharmacology, Interlaken, Switzerland, 2001. Lecture.
6. Mishani, E., Laky, D., Wajnblum, D., Chisin, R. PET radiopharmaceuticals dispensing unit. 49th Annual Meeting of the Society of Nuclear Medicine, Los Angeles, CA, USA, June 15-19, 2002.
7. Mishani, E., Levitzki, A., Abourbeh, G., Ortu, G., Ben-David, I., Rozen, Y., Lester, H., Freedman, N., Chisin, R. Novel Irreversible [C-11]EGFR-TK Inhibitors for Cancer Imaging Diagnosis. The 50 Annual Conference of the Society of Nuclear Medicine, New Orleans, Louisiana, USA, 2003. Lecture.
8. Mishani, E., Abourbeh, G., Ortu, Y., Rozen, Y., Ben David, I., Froimovici, S., Dissoki, S., Gazit, A., Levitzki, A. Novel EGFR Irreversible Tyrosine Kinase Inhibitors for the Diagnostic and Therapeutic Treatment of Cancer. The 15th International Symposium on Radiopharmaceutical Chemistry, Sydney, Australia, 2003. Poster.
9. Mishani, E., Abourbeh, G, Rozen, Y., Laki, D., Levitzky, A. Carbon-11 labeling of 4-Dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazolin-6-yl]-amides, a new class of EGFR irreversible inhibitors. The 15th International Symposium on Radiopharmaceutical Chemistry, Sydney, Australia, 2003. Lecture.